Tiny study on drug monitoring in scleroderma ends early

NCT ID NCT04244916

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study aimed to see if measuring the amount of mycophenolic acid in the blood could help doctors adjust the dose of mycophenolate mofetil (MMF) to better treat skin and lung problems in people with systemic sclerosis. Only 2 patients were enrolled before the study was terminated, so no meaningful results were obtained. The research was exploratory and did not lead to any clear conclusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

mycophenolate mofetil (MMF)

What this could lead to

If successful, it could help doctors personalize MMF dosing for better skin and lung outcomes in systemic sclerosis.

What could go wrong

The study was terminated early with only 2 participants, so no reliable conclusions can be drawn. The approach may not improve outcomes in practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

interstitial lung disease systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cochin hospital, AP-HP

    Paris, France, 75014, France